{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:11Z","timestamp":1755216731370,"version":"3.43.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Autologous hematopoietic stem cell transplant (ASCT) may be curative therapy for pediatric patients with relapsed\/refractory Hodgkin lymphoma (HL). Therapy for HL may involve pulmonary toxic modalities. Little information exists regarding pulmonary function in these patients post-ASCT. A retrospective chart review was performed for patients undergoing ASCT from February 2012 to December 2019. Lung disease was defined as a <jats:italic toggle=\"yes\">z<\/jats:italic>-score \u2264\u22121.7 in forced expiratory volume in the first second (FEV<jats:sub>1<\/jats:sub>), forced vital capacity (FVC), total lung capacity (TLC), or diffusing capacity of lung for carbon monoxide. Descriptive and limited statistical analyses were performed. Twenty-eight patients were included. Median age at diagnosis was 15 (2 to 19) and was 17 (4 to 21) at ASCT. Twenty-three received radiation before ASCT. Fourteen received brentuximab before, and 9 after, transplant. Nineteen met criteria for lung disease post-ASCT. Sixteen had lung disease before ASCT. Longitudinal trends for pulmonary function testing parameters did not reach statistical significance, however, FEV<jats:sub>1<\/jats:sub>, FVC, and TLC trended towards worsening immediately post-transplant. There was no statistically significant change in FEV<jats:sub>1<\/jats:sub>, FVC, or TLC at 2 years as compared with pretransplant data, suggesting no substantial difference from baseline. Diffusing capacity of lung for carbon monoxide showed statistically significant improvement at the 2 year timepoint (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03). This data reinforces the importance of close follow-up for these patients. Large cohort studies are necessary to identify risk factors so that possible mitigative strategies or alternate regimens could be used.<\/jats:p>","DOI":"10.1097\/mph.0000000000002301","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:21:47Z","timestamp":1630945307000},"page":"e926-e929","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Kimberly","family":"Davidow","sequence":"first","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Bunin","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia"},{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia"},{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason L.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia"},{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1080\/10428194.2017.1403601","article-title":"Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience","volume":"59","author":"Giulino-Roth","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular status in long-term survivors of Hodgkin\u2019s disease treated with chest radiotherapy","volume":"22","author":"Adams","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R7-20250804","first-page":"397","article-title":"New malignancies among cancer survivors: SEER cancer registries, 1973-2000. New Malignancies Following Hodgkin Lymphoma, Non-Hodgkin Lymphoma","volume":"62","author":"Curtis","year":"2008","journal-title":"J Epidemiol Community Health"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","article-title":"Lung function impairment in long-term survivors of Hodgkin\u2019s disease","volume":"6","author":"Lund","year":"1995","journal-title":"Ann Oncol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.15586","article-title":"Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin","volume":"183","author":"Faulk","year":"2018","journal-title":"Br J Haematol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:02:55Z","timestamp":1754337775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002301","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"2021-05-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}